Details About Generic Salt :: Carboplatin Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS CARBOPLATIN ALKYLATING AGENT | ANTI-NEOPLASTIC PK: D: 16 L (Vd) M: Hepatic E: Urine Indications & Dose: ADVANCED OVARIAN CANCER Combination therapy IV Adult 300mg/m2 as inf over 15-60min...
Read more
Details About Generic Salt :: Cisplatin Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS CISPLATIN ALKYLATING AGENT, PLATINUM COORDINATION COMPLEX | ANTI-NEOPLASTIC PK: D: Extensive E: Urine (>90%), feces (10%) Indications & Dose: ADVANCED BLADDER CANCER Mono therapy IV Adult 50-70mg/m2 as inf...
Read more
Details About Generic Salt :: Epirubicin Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS EPIRUBICIN ANTHRACYCLINE | ANTI-NEOPLASTIC ANTIBIOTIC PK: D: 21-27 L/kg (Vss) M: Hepatic E: Feces (34%-35%); urine (20%-27%) Indications & Dose: BREAST CANCER Combination therapy/Adjuvant therapy IV Adult 60mg/m2 over...
Read more
Details About Generic Salt :: Dacarbazine Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS DACARBAZINE ALKYLATING DRUG, TRIAZENE | ANTI-NEOPLASTIC PK: D: 0.6 L/kg (Vd) M: Hepatic E: Urine (~40% as unchanged drug) Indications & Dose: HODGKIN’S DISEASE Combination therapy IV Adult 375mg/m2...
Read more
Details About Generic Salt :: Etoposide Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS ETOPOSIDE PODOPHYLLOTOXIN DERIVATIVE | ANTI-NEOPLASTIC PK: A: Variable D: 7-17 L/m2(Vd) M: Hepatic E: Urine, faeces Indications & Dose: SMALL-CELL LUNG CANCER Combination therapy IV Adult 35mg/m2/day as inf...
Read more
Details About Generic Salt :: Dactinomycin Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS DACTINOMYCIN ANTIBIOTIC | ANTI-NEOPLASTIC PK: A: Rapid (IV) E: Urine & bile Indications & Dose: CHILDHOOD RHABDOMYOSARCOMA Combination therapy IV Adult 15µg/kg/day as inf over 10-15min 5 days Child...
Read more
Details About Generic Salt :: Irinotecan Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS IRINOTECAN TOPOISOMERASE INHIBITOR | HORMONAL ANTI-NEOPLASTIC PK: D: 33-150 L/m2 (Vd) M: Hepatic E: Urine Indications & Dose: COLORECTAL METASTATIC CARCINOMA Combination therapy/First-line therapy IV Adult 6wk (42 days)...
Read more
Details About Generic Salt :: Methotrexate Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 7H. DRUGS FOR INFLAMMATORY BOWEL DISEASE in 7. GASTROINTESTINAL SYSTEM METHOTREXATE ANTI-METABOLITE (ANTIFOLATE), IMMUNOSUPPRESSANT | ANTI-NEOPLASTIC, ANTI-RHEUMATIC also comes under 18A. Anti-Neoplastic Agents in 18. Anti-Neoplastic Agents, 12D. Anti-Rheumatic Drugs (DMARDs) in 12. Musculoskeletal Disorders & Pain, ...
Read more
Details About Generic Salt :: Bortezomib Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS BORTEZOMIB PROTEASOME INHIBITOR | ANTI-NEOPLASTIC PK: D: 498-1884 L/m2 (Vd) M: Hepatic Indications & Dose: MANTLE CELL LYMPHOMA IV Adult 1.3 mg/m2 twice weekly for 2 wk (days 1,...
Read more
Details About Generic Salt :: Cyclophosphamide Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents 18A. ANTI-NEOPLASTIC AGENTS in 18. ANTI-NEOPLASTIC AGENTS CYCLOPHOSPHAMIDE ALKYLATING AGENT | ANTI-NEOPLASTIC, IMMUNUOSUPPRESSANT also comes under 14A. Immunuosuppressants in 14. Immunology & Allergy PK: A: Well absorbed M: Hepatic E: Urine Indications & Dose: BREAST CANCER...
Read more